MAP Pharma (MAPP) Misses Q4 Views by 2c
- Relentless Selling of Twitter (TWTR) Continues
- Unusual 11 Mid-Day Movers 8/3: (GAI) (LXRX) (VTL) Higher; (ABGB) (LINE) (CVEO) Lower
- After five-week shut down, Greek stocks plummet
- General Motors (GM) July U.S. Auto Sales up 6.4%; Retail Deliveries Rose 14%
- EXOR to Acquire PartnerRe (PRE) for $140.50/Share
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q4 loss of $0.46, 2 cents worse than the analyst estimate of ($0.44).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ITG (ITG) CEO Bob Gasser Replaced by Jarrett Lilien
- Kosmos Energy Ltd. (KOS) Reports In-Line Q2 Loss
- Mesa Laboratories (MLAB) Tops Q1 EPS by 2c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!